References
1. YC-1, a novel activator of platelet guanylate cyclase: F.N. Ko, et al.; Blood 84: 4226 (1994). 2. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase: C.C. Wu, et al.; Br. J. Pharmacol. 116: 1973 (1995). 3. YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice: C.M. Teng, et al.; Eur. J. Pharmacol. 320: 161 (1997). 4. Mechanism of YC-1-induced activation of soluble guanylyl cyclase: A. Friebe & D. Koesling; Mol. Pharmacol. 53: 123 (1998). 5. BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclase: M. Koglin, et al.; BBRC 292: 1057 (2002). 6. Soluble guanylyl cyclase activator YC-1 protects white matter axons from nitric oxide toxicity and metabolic stress, probably through Na(+) channel inhibition: G. Garthwaite, et al.; Mol. Pharmacol. 61: 97 (2002). 7. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1: E.J. Yeo, et al.; J. Natl. Cancer Inst. 95: 516 (2003). 8. Versatile pharmacological actions of YC-1: anti-platelet to anticancer: Y.S. Chun, et al.; Cancer Lett. 207: 1 (2004) (Review). 9. A Novel Drug Binding Site on Voltage-Gated Sodium Channels in Rat Brain: D. R. Riddall, et al.; Mol. Pharmacol. 69: 278 (2006). 10. Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading: D.H. Shin, et al.; Cancer Lett. 255: 107 (2007). 11. YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway: S.Y. Wu, et al.; Br. J. Pharmacol. 155: 505 (2008). 12. YC-1 enhances natural killer cell differentiation from hematopoietic stem cells: S. Yun, et al.; Int. Im- munopharmacol. 10: 481 (2010). 13. Novel HTS strategy identifies TRAIL-sensitizing compounds acting specifically through the caspase-8 apop- totic axis: D. Finlay, et al.; PLoS One 5: e13375 (2010)USBio References
No references available
TDS
NCBI
UniProt
Tech Support
Customer Service
